Behavioral Effects of Single and Repeated Treatments with the Combination of D1 and D2 Antagonists

  • Ottavio Gandolfi
  • Rossella Dall’Olio
Part of the Advances in Behavioral Biology book series (ABBI, volume 39)


It is generally accepted that cerebral D2 dopamine receptors mediate the antidopaminergic activity of neuroleptics (Creese et al. 1976). This view is supported by the observations that all clinically effective antipsychotics are either mixed D1/D2 blockers or selective D2 dopamine antagonists (Christensen et al. 1984) and that a high correlation exists between the ability of neuroleptics to interact with the D2 receptors “in vitro” and their clinical efficacy (Seeman 1980). Nevertheless, the substituted benzamide sulpiride, which selectively blocks D2 dopamine receptors, is much weaker than classic neuroleptics in suppressing dopamine mediated behaviours (Jenner et al. 1978) and fails to antagonize apomorphine-induced stereotyped behaviour and to induce catalepsy (Costall and Naylor 1975; Jenner et al. 1978; Serra et al. 1983). In contrast, the selective D1 antagonist SCH 23390 does induce catalepsy and inhibits agonist-elicited stereotypy and hyperactivity (Iorio et al. 1983; Christensen et al. 1984), thus behaving as a classic neuroleptic agent. Therefore some antidopaminergic effects could be mediated by the concomitant blockade of D1 receptors which could contribute to the full activity of the typical antipsychotic drugs.


Stereotyped Behaviour Motility Count Subthreshold Dose Stereotyped Response Typical Antipsychotic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arnt, J., 1985, Behavioral stimulation is induced by separate D1 and D2 receptor sites in reserpine-pretreated but not in normal rats, Eur. J. Pharmacol., 113: 79.PubMedCrossRefGoogle Scholar
  2. Bartholini, G., 1976, Differential effect of neuroleptic drugs on dopamine turnover in the extrapiramidal and limbic system, J. Pharm. Pharmac., 28: 429.CrossRefGoogle Scholar
  3. Breese, G. R., and Mueller, R. A., 1985, SCH 23390 antagonism of a D-2 dopamine agonist depend upon catecholaminergic neurons, Eur. J. Pharmacol., 113:109. CrossRefGoogle Scholar
  4. Burt, D. R., Creese, J., and Snyder, S. H., 1977, Antipsychotic drugs: chronic treatment elevates dopamine receptor binding in brain, Science, 196: 326.PubMedCrossRefGoogle Scholar
  5. Christensen, A. V., Arnt, J., Hyttel, J., Larsen, J. J., and Svendsen, 0., 1984, Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics, Life Sci., 34: 1529.PubMedCrossRefGoogle Scholar
  6. Costall, B., and Naylor, R. J., 1975, Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine, Psychopharmacologia (Berlin), 43: 69.CrossRefGoogle Scholar
  7. Creese, I., Burt, D. R., and Snyder, S. H., 1976, Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs, Science, 192: 481.PubMedCrossRefGoogle Scholar
  8. Fuxe, K., Ogren, S. O., Hall, H., Agnati, L. F., Andersson, K., Kohler, C., and Schwarcz, R., 1980, Effect of chronic treatment with 1-sulpiride and haloperidol on central monoaminergic mechanisms, Adv. Biochem. Psychopharmacol., 24: 193.PubMedGoogle Scholar
  9. Iorio, L. C., Barnett, A., Leitz, F., Houser, V. P., and Korduba, C. A., 1983, SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic system, J. Pharmacol. Exp. Ther., 226: 462.PubMedGoogle Scholar
  10. Jenner, P., Clow, A., Reavill, C., Theodorou, A., and Marsden, C. D., 1978, A behavioral and biochemical comparison of dopamine receptor blockade produced by haloperidol with that produced by substituted benzamide drugs, Life Sci., 23: 545.PubMedCrossRefGoogle Scholar
  11. Klawans, H. L., and Rubovitz, R., 1972, An experimental model of tardive dyskynesia, J. Neural. Trans., 33: 235.CrossRefGoogle Scholar
  12. Mielke, D. H., Gallant, D. M., and Kessler, C., 1977, An evaluation of a unique new antipsychotic agent sulpiride: effects on serum prolactin and growth hormone levels, Am. J. Psychiat., 134: 1371.PubMedGoogle Scholar
  13. Montanaro, N., Dall’Olio, R., Gandolfi, 0., and Vaccheri, A., 1982, Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (-)-sulpiride and haloperidol, Eur. J. Pharmacol., 81: 1.PubMedCrossRefGoogle Scholar
  14. Pugh, M. T., O’Boyle, K. M., Molloy, A. G., and Waddington, J. L., 1985, Effects of the putative D-1 antagonist SCH 23390 on stereotyped behaviour induced by the D-2 agonist RU 24213, Psychopharmacology, 87: 308.PubMedCrossRefGoogle Scholar
  15. Radhakisun, F. S., and Van Ree, J. M., 1987, The hypomotility elicited by smal doses of apomorphine seems exclusively mediated by dopaminergic systems in the nucleus accumbens, Eur. J. Pharmacol., 136: 41.CrossRefGoogle Scholar
  16. Rupniak, N. M. J., Jilpatrick, G., Hall, M. D., Jenner, P., and Marsden, C. D., 1984, Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats, Psychopharmacology, 84: 512.PubMedCrossRefGoogle Scholar
  17. Scatton, B., Warms, P., Zivkovic, B., Depoortere, H., Dedek, K., and Bartholini, G., 1979, On the neuropharmacological spectra of “classical” (haloperidol) and “atypical” (benzamide derivatives) neuroleptics, in: “Sulpiride and Other Benzamides”, P. F. Spano, M. Trabucchi, G. U. Corsini, and G. L. Gessa, eds., Italian Brain Research Foundation Press, Milan, pp 53–66.Google Scholar
  18. Seeman, P., 1980, Brain dopamine receptors, Pharmacol. Rev., 32: 229.PubMedGoogle Scholar
  19. Serra, G., Van Ree, J. M., and De Vied, D., 1983, Influence of classical and atypical neuroleptics on apomorphine-induced behavioural changes on extinction of a conditioned avoidance response, J. Pharm. Pharmacol., 35: 255.PubMedCrossRefGoogle Scholar
  20. Sharp, P., Zetterstrom, T., Ljungberg, T., and Ungerstedt, U., 1987, A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis, Brain Res., 401: 322.PubMedCrossRefGoogle Scholar
  21. Stoof, J. C., and Verherjden, P. F. H. M., 1986, D-2 Receptor stimulation inhibits cyclic AMP formation brought about by D-1 receptor stimulation in rat neostriatum but not in nucleus accumbens, Eur. J. Pharmacol., 129: 205.PubMedCrossRefGoogle Scholar
  22. Tarsy, T., and Baldessarini, R. J., 1974, Behavioral supersensitivity to apomorphine following chronic treatment with drugs which interfere with synaptic function of cathecolamines, Neuropharmacology, 13: 927.PubMedCrossRefGoogle Scholar
  23. Trabucchi, M., Memo, M., Battaini, F., Reggiani, A., and Spano, P. F., 1980, Effect of long-term treatment with haloperidol and sulpiride on different types of dopaminergic receptors, Adv. Biochem. Psychopharmacol., 24: 275.PubMedGoogle Scholar
  24. Vaccheri, A., Dall’Olio, R., Gandolfi, 0., and Montanaro, N., 1986, Involvement of different dopamine receptors in rat diphasic motility response to apomorphine, Psychopharmacology, 89: 265.Google Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Ottavio Gandolfi
    • 1
  • Rossella Dall’Olio
    • 1
  1. 1.Institute of PharmacologyUniversity of BolognaBolognaItaly

Personalised recommendations